Guangdong Taiantang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
April 28, 2021 at 06:03 am EDT
Share
Guangdong Taiantang Pharmaceutical Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 775.917 million compared to CNY 747.543 million a year ago. Operating loss was CNY 66.452 million compared to operating Income of CNY 22.691 million a year ago. Net loss was CNY 59.185 million compared to net income of CNY 15.649 million a year ago. Basic loss per share from continuing operations was CNY 0.08 compared to basic earnings per share from continuing operations of CNY 0.02 a year ago.
Guangdong Taiantang Pharmaceutical Co Ltd is a company mainly engaged in the manufacturing of Chinese patent medicines and the primary processing of Chinese medicinal materials. The Company operates five segments. Chinese Patent Medicines Manufacturing Business segment is mainly responsible for the production and wholesale of Pibao cream, Qilin pill, Xinbao pill, Xinxin pill, Tongqiao Yixin pill, etc. Primary Processing Business segment of the traditional Chinese medicine materials is mainly responsible for planting, primary processing and sales of the ginseng and traditional Chinese medicine materials. Drug Wholesale and Retail Business segment is mainly responsible for the wholesale and retail of drugs and medical devices. Health Industry Development and Products Sales segment is mainly responsible for the development and sales of health concept real estate products. Medical Services segment is mainly responsible for the in-depth development of medical and elderly care services.